Orlistat for overweight subjects with nonalcoholic steatohepatitis.

Orlistat for overweight subjects with nonalcoholic steatohepatitis.

Detalles Bibliográficos
Main Authors:	Dowman, J, Stocken, D, Tomlinson, J, Newsome, P
Formato:	Journal article
Idioma:	English
Publicado:	2009

Títulos similares

Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
por: Dowman, J, et al.
Publicado: (2011)

Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle.
por: Dowman, J, et al.
Publicado: (2014)

Subcutaneous adipose tissue insulin resistance and lipolysis in patients with nonalcoholic steatohepatitis
por: Armstrong, M, et al.
Publicado: (2013)

Pathogenesis of non-alcoholic fatty liver disease.
por: Dowman, J, et al.
Publicado: (2010)

The diagnosis of non-alcoholic fatty liver disease: authors' reply
por: Dowman, J, et al.
Publicado: (2012)

Current therapeutic strategies in non-alcoholic fatty liver disease.
por: Dowman, J, et al.
Publicado: (2011)

Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
por: Armstrong, M, et al.
Publicado: (2013)

Necroptosis in Nonalcoholic Steatohepatitis
por: Jérémie Gautheron, PhD, et al.
Publicado: (2015-05-01)

The development of nonalcoholic steatohepatitis is subjected to breeder dependent variation in guinea pigs
por: D. H. Ipsen, et al.
Publicado: (2021-02-01)

Glucagon like peptide 1 analogue, Liraglutide, reduces adipose insulin resistance and hepatic de novo lipogenesis in Nonalcoholic Steatohepatitis: Sub-study results of a phase II randomised-control clinical trial
por: Armstrong, M, et al.
Publicado: (2013)

Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis
por: Armstrong, M, et al.
Publicado: (2014)

Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis.
por: Armstrong, M, et al.
Publicado: (2014)

Nonalcoholic Steatohepatitis: An Evolving Diagnosis
por: Brent A Neuschwander-Tetri
Publicado: (2000-01-01)

Oligonucleotide therapies for nonalcoholic steatohepatitis
por: Sixu Li, et al.
Publicado: (2024-06-01)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang Xiaobo
Publicado: (2022-08-01)

IMAGING DIAGNOSIS OF NONALCOHOLIC STEATOHEPATITIS
por: Anca Smaranda Farmazon, et al.
Publicado: (2018-09-01)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Gopanandan Parthasarathy, et al.
Publicado: (2020-04-01)

The metabolic basis of nonalcoholic steatohepatitis
por: Manu V. Chakravarthy, et al.
Publicado: (2020-10-01)

Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis
por: Mindy C.W. Lam, et al.
Publicado: (2012-07-01)

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
por: Armstrong, M, et al.
Publicado: (2015)

Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
por: Sebastião M.B. Duarte, et al.
Publicado: (2019-05-01)

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Mazen Noureddin, et al.
Publicado: (2020-10-01)

Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian survey
por: Helma P. Cotrim, et al.
Publicado: (2016-05-01)

Peroxisomal footprint in the pathogenesis of nonalcoholic steatohepatitis
por: S.M. Touhidul Islam, et al.
Publicado: (2020-09-01)

Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future
por: S. Gitto, et al.
Publicado: (2015-01-01)

Current Treatment Options for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Melanie D Beaton
Publicado: (2012-01-01)

Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Magdalena Mazurek, et al.
Publicado: (2023-02-01)

Nonalcoholic Steatohepatitis in Nondiabetic Obese Patients
por: Idilio Zamin, et al.
Publicado: (2002-01-01)

Human Nonalcoholic Steatohepatitis on a Chip
por: May S. Freag, et al.
Publicado: (2021-02-01)

Uncovered issues in the overview of nonalcoholic steatohepatitis
por: Chia-Chi Wang
Publicado: (2011-12-01)

The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis
por: Hui Xiang, et al.
Publicado: (2022-02-01)

Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis
por: Seonghwan Hwang, et al.
Publicado: (2021-10-01)

The regulatory state of nonalcoholic steatohepatitis and metabolism
por: Stephanie O. Omokaro, et al.
Publicado: (2020-10-01)

Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis
por: D.N. Amarapurkar, et al.
Publicado: (2006-01-01)

Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients
por: Alfredo Halpern, et al.
Publicado: (2010-01-01)

Comparison of Metformin and Orlistat in Anovulatory, Overweight and Obese Women with Polycystic Ovarian Syndrome
por: Uzma Gul, et al.
Publicado: (2023-06-01)

Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma: Brazilian Survey
por: Venancio Avancini Ferreira Alves, et al.
Publicado: (2016-08-01)

The Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis
por: Janine Dywicki, et al.
Publicado: (2022-02-01)

Nonalcoholic steatohepatitis and biliary sludge in people with metabolic syndrome
por: V G Radchenko, et al.
Publicado: (2016-09-01)

5-ALPHA-REDUCTASE-1 KNOCKOUT PROTECTS AGAINST HEPATOCARCINOGENESIS IN A MURINE MODEL OF NASH
por: Dowman, J, et al.
Publicado: (2012)